Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy (Q35144312)

6 August 2017

Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy (English)

1 reference

6 August 2017

0 references

1 reference

1 reference

Allan J Pantuck

1

1 reference

6 August 2017

Amnon Zisman

2

1 reference

6 August 2017

Frederich Dorey

3

1 reference

6 August 2017

Debby H Chao

4

1 reference

6 August 2017

Ken-Ryu Han

5

1 reference

6 August 2017

Jonathan Said

6

1 reference

6 August 2017

Barbara Gitlitz

7

1 reference

6 August 2017

Arie S Belldegrun

8

1 reference

6 August 2017

Robert A Figlin

9

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

6 August 2017

1 reference

6 August 2017

97

1 reference

6 August 2017

12

1 reference

6 August 2017

2995-3002

1 reference

Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma

6 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

Vascular endothelial growth factor receptor-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

21 January 2018

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

The natural history of metastatic renal cell carcinoma: a computer analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

An anatomical classification of renal tumors in the adult as a basis for prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

The results of radical nephrectomy for renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

Malignant neoplasms of the kidney; an analysis of 353 patients followed five years or more.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

Renal cell carcinoma.Natural history and results of treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

Diagnosis and management of renal cell carcinomaA clinical and pathologic study of 309 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

The Heidelberg classification of renal cell tumours.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

Improved prognostication of renal cell carcinoma using an integrated staging system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

The changing natural history of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

The treatment of renal cell carcinoma with human leukocyte alpha-interferon

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

Human Leukocyte Antigen Expression in Renal Cell Carcinoma Lesions Does Not Predict the Response to Interferon Therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

Renovascular hypertension after laparoscopic adrenalectomy in a patient with adrenal adenoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

Flow cytometric DNA analysis of interleukin-2 responsive renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

Cytogenetic studies in renal cell carcinoma patients receiving low-dose recombinant interleukin-2-based immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

VEGF-D promotes the metastatic spread of tumor cells via the lymphatics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11422

7 January 2021

Identifiers

DOI

10.1002/CNCR.11422

1 reference

6 August 2017

1 reference